Use of shenling baizhu in preparing medicament for treating post-recovery sequelae of covid-19 patient
Patent Information
- Application Number
- MYPI2025003726
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-21
- Filing Date
- 2023-10-31
- Publication Date
- 2024-06-21
AI Technical Summary
Patients with new coronavirus pneumonia often experience a series of sequelae symptoms after recovery, such as shortness of breath, fatigue, loss of appetite, and diarrhea, which seriously affect the quality of life, delay recovery, and increase the risk of reinfection. Existing drugs cannot effectively solve these symptoms. question.
Shenling Atractylodes granules produced by Beijing Handian Pharmaceutical Co., Ltd. are used to prepare drugs for the treatment of sequelae of patients with new coronavirus pneumonia through specific Chinese herbal medicine ratios and extraction processes, including ginseng, Poria cocos, and bran-fried Atractylodes. , yam, fried white lentils, lotus seeds, bran fried coix seed, amomum villosum, platycodon and licorice, made into granules, take 3g daily, which can significantly improve the patient's symptoms.
It can significantly improve the symptoms of shortness of breath, fatigue, loss of appetite and diarrhea in patients with new coronavirus pneumonia, improve the quality of life score, significantly improve the quality of life of patients, and has excellent industrial applicability.
Smart Images

Figure PI2025003726_DRAWING_001
Abstract
Description
Application of Shenling Baizhu in treating sequelae of novel coronavirus infection and improving quality of life
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to the Chinese patent application with application number 202211652297.0 filed with the State Intellectual Property Office of China on December 21, 2022, entitled “Application of Ginseng, Poria and Atractylodes in Treating Sequelae of Patients Infected with Novel Coronavirus and Improving the Quality of Life”, the entire contents of which are incorporated by reference into this application. Technical Field
[0003] The present disclosure belongs to the fields of medicine and traditional Chinese medicine, and specifically relates to the application of ginseng, Poria cocos, and Atractylodes macrocephala in treating sequelae of patients infected with the novel coronavirus, especially patients with pneumonia caused by the novel coronavirus, and improving their quality of life. Background Art
[0004] Coronavirus disease 2019 (COVID-19) is one of the most serious public health emergencies of this century. According to the latest real-time statistics from the World Health Organization, as of December 5, 2022, the global cumulative number of confirmed cases of COVID-19 has exceeded 644 million, with a cumulative death toll of 6.652 million. According to domestic and international literature, the novel coronavirus not only damages the respiratory system, but also the lungs, heart, liver, kidneys, blood system, and reproductive system. It also causes severe damage to multiple systems in patients recovering from the disease, leading to a series of sequelae, including fatigue, cough, shortness of breath, poor appetite, low-grade fever, night sweats, constipation or diarrhea, chest tightness, palpitations, chronic bleeding, sensory impairment, and movement disorders. In January 2021, The Lancet, a leading global medical journal, published a follow-up study of 1,733 COVID-19 patients after discharge, conducted by Wuhan Jinyintan Hospital and other centers. The results showed that over 70% (76%) of patients continued to experience at least one symptom six months after the acute infection. Fatigue or muscle weakness (63%) and sleep disorders (26%) are the most common symptoms (Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study [J]. Lancet. 2021; 397(10270): 220-232). The above sequelae greatly affect the quality of life of patients who have recovered from COVID-19, and will delay the patient's complete recovery, making it difficult for the patient's immunity to recover, thereby laying the groundwork for the risk of reinfection. According to experts' predictions, the new coronavirus has undergone continuous mutations, and although its virulence has decreased, its infectiousness has increased, and its transmission has become more covert. The new coronavirus will coexist with humans for a long time, and patients with pneumonia caused by infection with the new coronavirus will continue to appear in the population. Therefore, there is a continuous clinical need to provide drugs to treat sequelae and improve the quality of life of clinically cured patients with COVID-19.
[0005] The Shenling Baizhu Granules produced by Beijing Handian Pharmaceutical Co., Ltd. are the only Shenling Baizhu Granules approved by the former State Food and Drug Administration (National Medicine Standard No. Z20040416). They are available in 3g bags, with a daily dosage of 27.9g of the herbal remedy. This specification is exclusive to Handian. Other Shenling Baizhu Granules on the market use the same name but with different formulas and ingredients (6g bags, with a daily dosage of 13.95g). Beijing Handian Pharmaceutical Co., Ltd.'s process involves four steps: volatile oil extraction, water extraction, ethanol extraction, and raw yam powder. Other granule manufacturers use a two-step process: volatile oil extraction and water extraction. Shenling Baizhu powders and pills all use raw yam powder as the herbal remedy, and the material base of the Shenling Baizhu Granules produced by Beijing Handian Pharmaceutical Co., Ltd. is significantly different. The formulation and molding processes also differ significantly. Other Shenling Baizhu Granules adhere to the 1998 ministerial standard, consisting of 1 part clear paste, 2 parts sucrose, and 2.5 parts dextrin. The Shenling Baizhu Granules produced by Beijing Handian Pharmaceutical Co., Ltd. comply with the 2005 version of the national standard and are made of 1 part of clear paste and 0.4 parts of lactose, which greatly reduces the amount of auxiliary materials consumed by patients and increases patient compliance.
[0006] Beijing Handian Pharmaceutical Co., Ltd. has also been granted a national invention patent, patent number ZL200510086669.8, for its unique process based on the active ingredients of its Shenling Baizhu Granules. To alleviate the sequelae of pneumonia caused by the novel coronavirus and help patients recover quickly and return to normal life, the inventors have trialed using Shenling Baizhu Granules produced by Beijing Handian Pharmaceutical Co., Ltd. to treat the sequelae of pneumonia caused by the novel coronavirus, achieving significant results.
[0007] Summary of the Invention
[0008] In response to the deficiencies in the prior art, the present disclosure provides new medical uses of Shenling Baizhu, especially Shenling Baizhu Granules (National Medicine Standard No. Z20040416) produced by Beijing Handian Pharmaceutical Co., Ltd., in treating the sequelae of patients with novel coronavirus pneumonia and improving the quality of life of patients after recovery.
[0009] To achieve the above technical effects, the present disclosure adopts the following technical solutions:
[0010] The use of ginseng, Poria and Atractylodes macrocephala in the preparation of a drug for treating sequelae of patients with novel coronavirus pneumonia and improving their quality of life; the sequelae are selected from at least one of shortness of breath, fatigue, loss of appetite and diarrhea; the raw materials of the ginseng, Poria and Atractylodes macrocephala are composed of the following Chinese medicinal materials in parts by weight:
[0011] 400 parts of ginseng, 400 parts of poria, 400 parts of stir-fried atractylodes macrocephala with bran, 400 parts of yam, 300 parts of stir-fried white lentils, 200 parts of lotus seeds, 200 parts of stir-fried coix seeds with bran, 200 parts of amomum villosum, 200 parts of platycodon grandiflorum and 400 parts of liquorice.
[0012] Optionally, the sequelae further include at least one selected from nausea, fullness in the abdomen and weak bowel movements.
[0013] Optionally, improving the quality of life of patients with novel coronavirus pneumonia after recovery means that after the ginseng, Poria and Atractylodes macrocephala are administered to patients with novel coronavirus pneumonia, the patient's SF12 scale score is significantly decreased compared with the score before treatment, and the P value is at least less than 0.05.
[0014] Optionally, the drug disclosed herein is a clinically acceptable formulation.
[0015] Optionally, the medicine is selected from decoction, pills, powders, granules, tablets or capsules.
[0016] As an optional embodiment, the drug is a granule, which is prepared by the following steps:
[0017] I. Take each Chinese herbal medicine according to the weight portion;
[0018] II. Grind the Chinese yam into fine powder, pass through a 100-mesh sieve, and set aside;
[0019] III. Amomum villosum was extracted by steam distillation to the end of the volatile oil, and the aqueous solution after distillation was collected in another device; Amomum villosum residues and ginseng, bran fried Atractylodes macrocephala plus 4-5 times by weight of 95% ethanol soaked for 24 hours, heated to reflux for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 65 ℃ relative density of 1.00-1.15 clear paste to obtain alcohol extract A; dregs were then added 4-5 times by weight of 50% ethanol reflux extraction for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 80 ℃ relative density of 1.12-1.13 clear paste to obtain alcohol extract B, ethanol extraction of the dregs standby;
[0020] IV. Poria, fried white lentils, lotus seeds, fried coix seed, platycodon and licorice were decocted with 8-10 times by weight of water for 2 hours, filtered, and the residue was combined with the residue prepared after ethanol extraction in step III, and then 8 times by weight of water was added and boiled together for 1.5 hours, filtered, and the two filtrates were combined with the distilled aqueous solution obtained in step III, allowed to stand, filtered, and the filtrate was concentrated to a relative density of 1.20 at 80°C. The alcohol extracts A and B were added and concentrated to a clear paste having a relative density of 1.30-1.34 at 80°C;
[0021] V. Mix the yam powder obtained in step II into the clear paste obtained in step IV, dry it at 60°C to form a dry paste, and grind it to obtain a powder;
[0022] VI. Take 1 part by weight of the powder obtained in step V, 0.4 parts by weight of powdered sugar, mix well, granulate with 70%-75% ethanol, dry the whole grain, spray the volatile oil obtained in step III of Amomum villosum, mix well, and make 1000g.
[0023] As an optional embodiment, the above granules are administered to a subject in need three times a day, 3 g each time, which is equivalent to a crude drug amount of 27.9 g / day.
[0024] Through clinical observation, Shenling Baizhu Granules can effectively treat the sequelae of COVID-19 patients after recovery, thereby improving the quality of life of patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The present disclosure will be further described below with reference to the accompanying drawings.
[0026] Figure 1 shows a sample form of the SF-12 quality of life assessment scale. DETAILED DESCRIPTION
[0027] The 2019 novel coronavirus (2019-nCoV) not only causes severe damage to the respiratory system of infected patients, but also has a huge impact on the patient's systemic biological system, bringing patients prolonged and long-term sequelae, which greatly affects the patient's physical health and quality of life. The inventors conducted a clinical observation trial on the effect of ginseng, Poria and Atractylodes macrocephala preparations on the quality of life of patients with new coronary pneumonia after recovery in four hospitals in Hubei Province, namely Tongshan County People's Hospital, Sinopharm Dongfeng General Hospital, Xianning Central Hospital and Yangxin County People's Hospital. After nearly a month of intervention treatment, the patient's symptoms such as shortness of breath, fatigue, loss of appetite, and diarrhea were significantly improved, and the quality of life was significantly improved.
[0028] The present disclosure is described below with reference to specific examples. Those skilled in the art will appreciate that these examples are only used to illustrate the present disclosure and are not intended to limit the scope of the present disclosure in any way.
[0029] The experimental methods in the following examples are conventional methods unless otherwise specified. The medicinal materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.
[0030] In the field of Traditional Chinese Medicine, clinical symptoms are described using their own proprietary terminology. For example, fatigue is called "tiredness and weakness," loss of appetite is called "poor appetite," and diarrhea is called "loose stools." In the following examples, the relevant clinical symptoms are generally described using Traditional Chinese Medicine terminology.
[0031] Example 1 Preparation of Shenling Baizhu Granules
[0032] Prescription: 400g ginseng, 400g Poria cocos, 400g stir-fried Atractylodes macrocephala with bran, 400g Chinese yam, 300g stir-fried white lentils, 200g lotus seeds, 200g stir-fried Coix seeds, 200g Amomum villosum, 200g Platycodon grandiflorum and 400g licorice.
[0033] Production process:
[0034] I. Take each Chinese herbal medicine according to the prescription;
[0035] II. Grind the Chinese yam into fine powder, pass through a 100-mesh sieve, and set aside;
[0036] III. Amomum villosum was extracted by steam distillation to the end of the volatile oil, and the aqueous solution after distillation was collected in another device; Amomum villosum residues and ginseng, bran fried Atractylodes macrocephala plus 4-5 times by weight of 95% ethanol soaked for 24 hours, heated to reflux for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 65 ℃ relative density of 1.00-1.15 clear paste to obtain alcohol extract A; dregs were then added 4-5 times by weight of 50% ethanol reflux extraction for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 80 ℃ relative density of 1.12-1.13 clear paste to obtain alcohol extract B, ethanol extraction of the dregs standby;
[0037] IV. Poria, fried white lentils, lotus seeds, fried coix seed, platycodon and licorice were decocted with 8-10 times by weight of water for 2 hours, filtered, and the residue was combined with the residue prepared after ethanol extraction in step III, and then 8 times by weight of water was added and boiled together for 1.5 hours, filtered, and the two filtrates were combined with the distilled aqueous solution obtained in step III, allowed to stand, filtered, and the filtrate was concentrated to a relative density of 1.20 at 80°C. The alcohol extracts A and B were added and concentrated to a clear paste having a relative density of 1.30-1.34 at 80°C;
[0038] V. Mix the yam powder obtained in step II into the clear paste obtained in step IV, dry it at 60°C to form a dry paste, and grind it to obtain a powder;
[0039] VI. Take 1 part by weight of the powder obtained in step V, 0.4 parts by weight of powdered sugar, mix well, granulate with 70%-75% ethanol, dry the whole grain, spray the volatile oil of Amomum villosum obtained in step III, mix well, make 1000g, and pack 3g per bag.
[0040] Dosage and usage: Three times a day, 1 bag each time.
[0041] Example 2 Intervention effect of Shenling Baizhu granules on the quality of life of patients with new coronary pneumonia after recovery
[0042] This example was conducted in Tongshan County People's Hospital, Sinopharm Dongfeng General Hospital, Xianning Central Hospital and Yangxin County People's Hospital in Hubei Province from September 2021 to July 2022.
[0043] 1. Case distribution
[0044] A total of 313 subjects were enrolled in the study, and 313 cases were completed, accounting for 100% of the enrolled cases. After excluding 8 cases whose ages were outside the range of 18-80 years old, 305 cases were included in the analysis set.
[0045] 2. General information of the case
[0046] There were 166 males (54.43%) and 139 females (45.57%); 303 (99.34%) were Han Chinese; the average age was 46.34±14.09 years, with the youngest being 2 years old and the oldest being 84 years old; the average weight was 63.41±7.51 kg.
[0047] 3. Vital signs
[0048] Body temperature, respiration, blood pressure, and heart rate were basically normal at enrollment, and no obvious abnormalities were observed during the study.
[0049] 4. Dosage regimen
[0050] During the study, the average number of days of medication was 28.09 ± 0.88 days, the shortest number of days was 25 days, the longest number of days was 32 days, and the median number of days was 28 days. The day before the subject started taking the medication was recorded as day 0, the day of medication start was recorded as day 1, and so on, up to day 28.
[0051] The specific dosage regimen is: Shenling Baizhu Granules 3 times a day, 1 bag each time (3g / bag), for 28 consecutive days. Shenling Baizhu Granules are produced by Beijing Handian Pharmaceutical Co., Ltd., with the same production process as described in Example 1, and the batch numbers are 211032, 211134, and 211232.
[0052] 5. Efficacy evaluation indicators
[0053] The primary efficacy indicator was the disappearance rate of shortness of breath, fatigue, poor appetite, and loose stools, and the secondary indicator was the SF-12 (quality of life assessment scale, see Figure 1).
[0054] 6. Data Collection
[0055] All enrolled subjects visited the hospital on days 0, 14, and 28 to collect symptoms and score records. The data on day 0 was recorded as "Visit 1", the data on day 14 was recorded as "Visit 2", and the data on day 28 was recorded as "Visit 3". The three groups of data were statistically analyzed.
[0056] 7. Statistics and Analysis
[0057] Statistical analysis will be performed using SAS 9.4 (or above) statistical analysis software.
[0058] All statistical tests were two-sided, and the test statistics and their corresponding P values were given. Differences were considered statistically significant when P < 0.05.
[0059] For quantitative data, the number of cases, mean, standard deviation, minimum, median, maximum, upper quartile (Q1), lower quartile (Q3), and 95% confidence interval (95% CI) were described. The t-test was used to compare treatment groups. If the influence of covariates was considered, analysis of covariance was performed. For time-series data, the median survival time was described and Kaplan-Meier curves were plotted. The log-rank test was used to compare the difference in median survival time between the two groups. If the influence of center or other factors was considered, Cox regression analysis was performed.
[0060] Qualitative data should describe the number and percentage of cases in each category. For enumeration data, the chi-square test and Fisher's exact test were used for comparisons between treatment groups. For ranked data, the Wilcoxon rank-sum test was used for comparisons between treatment groups. If the influence of center or other factors was considered, the CMH chi-square test or logistic regression was used.
[0061] 8. Intervention efficacy
[0062] 8.1 Improvement of major symptoms
[0063] The results are shown in Tables 1, 2 and 3.
[0064] Table 1 Measured values of main symptom scores
[0065] Table 2 Differences in main symptom scores
[0066] Table 3 Disappearance rate of main symptoms
[0067] 8.1.1 Shortness of Breath: With intervention, the mean score at Visit 2 decreased by 1.44±1.32 points relative to baseline, and the mean score at Visit 3 decreased by 2.4±1.8 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in shortness of breath scores with treatment. At the end of the study, the shortness of breath symptom resolution rate was 90%.
[0068] 8.1.2 Symptoms of fatigue and tiredness:
[0069] During the study, the intervention reduced scores by an average of 1.91±1.24 points at Visit 2 and 3.16±1.45 points at Visit 3 relative to baseline. Mixed-effects model analysis and paired-rank tests revealed statistically significant differences (p<0.05), indicating a significant decrease in fatigue and burnout symptom scores. By the end of the study, the fatigue and burnout symptom resolution rate was 89.7%.
[0070] 8.1.3 Symptoms of poor appetite:
[0071] During the study period, the intervention reduced the mean score at Visit 2 by 1.94±1.22 points, and the mean score at Visit 3 by 3.02±1.29 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in anorexia symptom scores with treatment. By the end of the study, the anorexia symptom resolution rate was 97.94%.
[0072] 8.1.4 Symptoms of loose stools:
[0073] During the study, the intervention reduced the mean score at Visit 2 by 1.05±1.54 points, and the mean score at Visit 3 by 1.57±1.65 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in the loose stool symptom score with treatment. By the end of the study, the loose stool symptom resolution rate was 91.48%.
[0074] 8.2 Secondary Symptom Efficacy Outcomes
[0075] The results are shown in Tables 4, 5 and 6.
[0076] Table 4 Measured values of minor symptom scores
[0077] Table 5 Differences in minor symptom scores
[0078] Table 6 Disappearance rate of minor symptoms
[0079] 8.2.1 Nausea and vomiting symptoms:
[0080] During the study period, the intervention reduced the mean score at Visit 2 by 0.76±0.68 points, and the mean score at Visit 3 by 1.04±0.76 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in nausea and vomiting scores with treatment. By the end of the study, the nausea and vomiting symptom resolution rate was 98.3%.
[0081] 8.2.2 Symptoms of distension and fullness:
[0082] During the study period, the intervention reduced the mean score at Visit 2 by 0.7±0.66 points, and the mean score at Visit 3 by 0.89±0.76 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in the score of abdominal distension with treatment. By the end of the study, the rate of resolution of abdominal distension was 97.18%.
[0083] 8.2.3 Symptoms of weak bowel movements:
[0084] During the study period, the intervention reduced the mean score at Visit 2 by 0.47±0.67 points, and the mean score at Visit 3 by 0.7±0.73 points relative to baseline. Mixed-effects model analysis and paired-rank test revealed statistically significant differences (p<0.05), indicating a significant decrease in the weak stool symptom score with treatment. By the end of the study, the weak stool symptom resolution rate was 87.85%.
[0085] 8.3 SF12 Scale (Quality of Life Assessment Score) Scoring Results
[0086] The results are shown in Tables 7 and 8.
[0087] Table 7 Measured values of SF12 scale scores
[0088] Table 8 SF12 scale score difference
[0089] Through intervention treatment, the average score of Visit 2 during the study period increased by 9.16±11.59 points compared with the baseline, and the average score of Visit 3 decreased by 17.06±12.42 points compared with the baseline. The mixed effects model and paired rank test analysis showed that the differences were statistically significant (p<0.05), indicating that the SF12 scale score was significantly improved compared with the baseline through treatment.
[0090] 9. Conclusion
[0091] Ginseng, Poria and Atractylodes can significantly treat various sequelae symptoms of patients recovering from COVID-19 and significantly improve patients' quality of life scores.
[0092] The foregoing description is merely an example of an optional embodiment of the present disclosure and is not intended to limit the present disclosure. Those skilled in the art will readily appreciate that the present disclosure is susceptible to various modifications and variations. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present disclosure shall be included within the scope of protection of the present disclosure. Industrial Applicability
[0093] The present disclosure provides the use of ginseng, Poria, and Atractylodes macrocephala in the preparation of a medicament for treating the sequelae of COVID-19 patients after recovery and improving their quality of life; the sequelae are selected from at least one of shortness of breath, fatigue, loss of appetite, and diarrhea. The ginseng, Poria, and Atractylodes macrocephala provided in the present disclosure can significantly treat various sequelae of COVID-19 patients after recovery and significantly improve their quality of life scores, demonstrating excellent industrial applicability.
Claims
1. The use of ginseng, Poria and Atractylodes macrocephala in the preparation of a drug for treating sequelae of patients with novel coronavirus pneumonia and improving the quality of life; the sequelae are selected from at least one of shortness of breath, fatigue, loss of appetite, and diarrhea; the raw materials of the ginseng, Poria and Atractylodes macrocephala are composed of the following Chinese medicinal materials in parts by weight: 400 parts of ginseng, 400 parts of poria, 400 parts of stir-fried atractylodes macrocephala with bran, 400 parts of yam, 300 parts of stir-fried white lentils, 200 parts of lotus seeds, 200 parts of stir-fried coix seeds with bran, 200 parts of amomum villosum, 200 parts of platycodon grandiflorum and 400 parts of liquorice.
2. The use according to claim 1, characterized in that The sequelae also include at least one selected from nausea, fullness in the abdomen and weak bowel movements.
3. The use according to claim 1, characterized in that The improving the quality of life of patients with novel coronavirus pneumonia after recovery means that after the ginseng, Poria and Atractylodes macrocephala are administered to patients with novel coronavirus pneumonia, the patient's SF12 scale score is significantly reduced compared with the score before treatment, and the P value is at least less than 0.
05.
4. The use according to any one of claims 1 to 3, characterized in that The medicine is a clinically acceptable preparation.
5. The use according to claim 4, characterized in that The medicine is selected from decoction, pills, powders, granules, tablets or capsules.
6. The use according to claim 5, characterized in that The drug is a granule, which is prepared by the following steps: I. Take each Chinese herbal medicine according to the weight portion; II. Grind the Chinese yam into fine powder, pass through a 100-mesh sieve, and set aside; III. Amomum villosum was extracted by steam distillation to the end of the volatile oil, and the aqueous solution after distillation was collected in another device; Amomum villosum residues and ginseng, bran fried Atractylodes macrocephala plus 4-5 times by weight of 95% ethanol soaked for 24 hours, heated to reflux for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 65 ℃ relative density of 1.00-1.15 clear paste to obtain alcohol extract A; dregs were then added 4-5 times by weight of 50% ethanol reflux extraction for 3 hours, filtered, the filtrate was recovered by ethanol, and concentrated to 80 ℃ relative density of 1.12-1.13 clear paste to obtain alcohol extract B, ethanol extraction of the dregs standby; IV. Poria, fried white lentils, lotus seeds, fried coix seed, platycodon and licorice were decocted with 8-10 times by weight of water for 2 hours, filtered, and the residue was combined with the residue prepared after ethanol extraction in step III, and then 8 times by weight of water was added and boiled together for 1.5 hours, filtered, and the two filtrates were combined with the distilled aqueous solution obtained in step III, allowed to stand, filtered, and the filtrate was concentrated to a relative density of 1.20 at 80°C. The alcohol extracts A and B were added and concentrated to a clear paste having a relative density of 1.30-1.34 at 80°C; V. Mix the yam powder obtained in step II into the clear paste obtained in step IV, dry it at 60°C to form a dry paste, and grind it to obtain a powder; VI. Take 1 part by weight of the powder obtained in step V, 0.4 parts by weight of powdered sugar, mix well, granulate with 70%-75% ethanol, dry the whole grain, spray the volatile oil obtained in step III of Amomum villosum, mix well, and make 1000g.
7. The use according to claim 6, characterized in that When the granules are administered to a subject in need, 3 g is taken 3 times a day, which is equivalent to a crude drug dosage of 27.9 g / day.
